Marksans Pharma Ltd (BOM:524404) Stock Price, Trades & News

Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	2.9
Equity-to-Asset	0.78
Debt-to-Equity	0.11
Debt-to-EBITDA	0.5
Interest Coverage	20.81
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	10.93	Distress Grey Safe
Beneish M-Score	-2.09	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

6/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	13.5
	3-Year EBITDA Growth Rate	16.6
	3-Year EPS without NRI Growth Rate	10.2
	3-Year FCF Growth Rate	17.8
	3-Year Book Growth Rate	19.5

Momentum Rank

9/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	26.96
	9-Day RSI	34.44
	14-Day RSI	41.64
	3-1 Month Momentum %	38.42
	6-1 Month Momentum %	61.47
	12-1 Month Momentum %	13.61

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	5.17
	Quick Ratio	3.32
	Cash Ratio	1.89
	Days Inventory	264.14
	Days Sales Outstanding	73.71
	Days Payable	88.34

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	0.32
	Dividend Payout Ratio	0.09
	3-Year Dividend Growth Rate	47.4
	Forward Dividend Yield %	0.37
	5-Year Yield-on-Cost %	2.27
	3-Year Average Share Buyback Ratio	-0.5
	Shareholder Yield %	-0.34

Profitability Rank

9/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	56.72
	Operating Margin %	17.02
	Net Margin %	14.16
	EBITDA Margin %	23.16
	FCF Margin %	11.1
	OCF Margin %	15.52
	ROE %	15.33
	ROA %	11.89
	ROIC %	15.9
	3-Year ROIIC %	10.32
	ROC (Joel Greenblatt) %	27.36
	ROCE %	19.31
	Years of Profitability over Past 10-Year	10

GF Value Rank

5/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	26.68
	Forward PE Ratio	24.17
	PE Ratio without NRI	26.68
	Shiller PE Ratio	49.68
	Price-to-Owner-Earnings	29.59
	PEG Ratio	1.77
	PS Ratio	3.79
	PB Ratio	3.69
	Price-to-Tangible-Book	3.9
	Price-to-Free-Cash-Flow	34.07
	Price-to-Operating-Cash-Flow	24.37
	EV-to-EBIT	18.03
	EV-to-EBITDA	15.42
	EV-to-Revenue	3.57
	EV-to-FCF	35.05
	Price-to-GF-Value	1.07
	Price-to-Projected-FCF	2.55
	Price-to-DCF (Earnings Based)	1.12
	Price-to-DCF (FCF Based)	3.67
	Price-to-Median-PS-Value	1.91
	Price-to-Peter-Lynch-Fair-Value	1.87
	Price-to-Graham-Number	2.15
	Price-to-Net-Current-Asset-Value	5.92
	Price-to-Net-Cash	71.17
	Earnings Yield (Greenblatt) %	5.55
	FCF Yield %	2.94
	Forward Rate of Return (Yacktman) %	16.16

Financials (Next Earnings Date:2026-08-13 Est.)

Annual Quarterly TTM

BOM:524404's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Marksans Pharma Ltd Executives

Details

GF Value™: ₹230.13

BOM:524404

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with 524404. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil ₹)	29,509.39
	EPS (TTM) (₹)	9.23
	Beta	1.9907
	3-Year Sharpe Ratio	0.77
	3-Year Sortino Ratio	1.68
	Volatility %	54.06
	14-Day RSI	41.64
	14-Day ATR (₹)	11.104029
	20-Day SMA (₹)	264.375
	12-1 Month Momentum %	13.61
	52-Week Range (₹)	156 - 281.4
	Shares Outstanding (Mil)	453.16

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Marksans Pharma Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Marksans Pharma Ltd Stock Events

Financials Calendars

Event	Date	Price (₹)
Second quarter earnings conference call for 2027	2026-11-13 17:00	In 112 days
Second quarter earnings results for 2027	2026-11-13	In 111 days
INR 0.900000 Cash Dividend	2026-08-20	In 26 days
First quarter earnings conference call for 2027	2026-08-13 16:00	In 20 days
First quarter earnings results for 2027	2026-08-13	In 19 days
General meeting for 2026	2026-08-07 09:00	In 14 days
Annual report for 2026	2026-07-30	In 5 days
Fourth quarter earnings conference call for 2026	2026-05-27 16:30	254.45 (+15.29%)
Fourth quarter earnings results for 2026	2026-05-27	254.45 (+15.29%)
Third quarter earnings conference call for 2026	2026-02-06 16:00	179.55 (+3.76%)

Show

Entries

Marksans Pharma Ltd Frequently Asked Questions

What is Marksans Pharma Ltd(BOM:524404)'s stock price today?

The current price of BOM:524404 is ₹246.25. The 52 week high of BOM:524404 is ₹281.40 and 52 week low is ₹156.00.

When is next earnings date of Marksans Pharma Ltd(BOM:524404)?

The next earnings date of Marksans Pharma Ltd(BOM:524404) is 2026-08-13 Est..

Does Marksans Pharma Ltd(BOM:524404) pay dividends? If so, how much?

The Dividend Yield % of Marksans Pharma Ltd(BOM:524404) is 0.32% (As of Today), Highest Dividend Payout Ratio of Marksans Pharma Ltd(BOM:524404) was 0.55. The lowest was 0.02. And the median was 0.06. The Forward Dividend Yield % of Marksans Pharma Ltd(BOM:524404) is 0.37%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
No Press Release

Articles on Marksans Pharma Ltd

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.